This article is more than 5 years old. Information may no longer be current.
Aerie initiates phase 2b study of combination glaucoma agent
Click Here to Manage Email Alerts
Aerie Pharmaceuticals Inc. announced in a press release that it has begun a 28-day phase 2b clinical trial of PG324, a fixed-combination of AR-13324 and latanoprost.
The trial will compare two concentrations of PG324 to latanoprost and to AR-13324 dosed once daily in 300 patients with glaucoma or ocular hypertension.
The intended result will be superiority of PG324 to each of its components, as measured by lowering of the mean diurnal intraocular pressure on day 28 compared to baseline.
As stated in the press release, Aerie believes that PG324 would lower IOP through four potential actions: increasing fluid outflow through the trabecular pathway, increasing fluid outflow through the uveoscleral pathway, reducing fluid production in the eye and potentially also lowering episcleral venous pressure.
Aerie Chief Medical Officer Brian Levy, OD, MSc, stated in the press release that previous phase 2B testing of AR-1334 showed IOP lowering in the range of 5.7 mm Hg to 6.2 mm Hg.
“We believe that adding latanoprost to AR-13324 in our fixed-combination product has the potential to provide for maximal IOP lowering in patients with glaucoma and ocular hypertension, by targeting all currently known mechanisms of action that affect IOP.”